# Genprex Inc. (GNPX)

Source: https://www.quantisnow.com/company/GNPX
Generated: 2026-11-22T07:15:33.783Z

- Ticker: GNPX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2018
- SEC CIK: 0001595248
- Website: genprex.com

## About

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes who currently have limited treatment options. The company works with institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Its lead product candidate is REQORSA (GPX-001), which is in preclinical stage for the treatment of non-small cell lung cancer (NSCLC). It is also developing GPX-002, a preclinical stage gene therapy for diabetes. The company also offers ONCOPREX, a nanoparticle delivery system. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

## Latest GNPX news and filings

- 2026-11-19 12:00 UTC [Genprex Presents Preclinical Data Identifying TROP2 as a Potential Predictive Biomarker for Reqorsa® Gene Therapy in Lung Cancer](https://www.quantisnow.com/insight/genprex-presents-preclinical-data-identifying-trop2-as-a-potential-predictive-6799808)
- 2026-11-13 21:17 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Genprex Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-genprex-inc-6790765)
- 2026-11-11 12:00 UTC [Genprex to Highlight Dual Delivery Strategy for Diabetes Gene Therapy at Future of Cell and Gene Therapy Symposium](https://www.quantisnow.com/insight/genprex-to-highlight-dual-delivery-strategy-for-diabetes-gene-therapy-6785141)
- 2026-11-05 12:01 UTC [SEC Form 8-K] [Genprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/genprex-inc-filed-sec-form-8-k-other-events-financial-statements-6774542)
- 2026-11-05 12:00 UTC [Genprex Presents Data Showing Reqorsa® Gene Therapy Activates Cellular Repair and Maintenance Programs Linked to Aging Biology in Patients, Supporting TUSC2 as a Key Regulator of Resilience to Aging-Associated Stress](https://www.quantisnow.com/insight/genprex-presents-data-showing-reqorsa-gene-therapy-activates-cellular-repair-6774446)
- 2026-11-04 12:01 UTC [SEC Form 8-K] [Genprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/genprex-inc-filed-sec-form-8-k-other-events-financial-statements-6771260)
- 2026-11-04 12:00 UTC [Genprex Announces New Research Identifying TROP2 as a Potential Predictive Biomarker to Reqorsa® Gene Therapy in Lung Cancer](https://www.quantisnow.com/insight/genprex-announces-new-research-identifying-trop2-as-a-potential-predictive-6771227)
- 2026-10-28 11:01 UTC [SEC Form 8-K] [SEC Form 8-K filed by Genprex Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-genprex-inc-6760449)
- 2026-10-28 11:00 UTC [Genprex to Present TUSC2 Research from Sponsored Collaboration with Meharry Medical College at the Gerontological Society of America 2026 Annual Scientific Meeting](https://www.quantisnow.com/insight/genprex-to-present-tusc2-research-from-sponsored-collaboration-with-meharry-6760416)
- 2026-10-21 11:01 UTC [SEC Form 8-K] [SEC Form 8-K filed by Genprex Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-genprex-inc-6752858)
- 2026-10-21 11:00 UTC [Genprex Highlights New Preclinical Data Identifying Role of TUSC2, the Gene Used in REQORSA®, in Maintaining Cellular Function During Brain Aging](https://www.quantisnow.com/insight/genprex-highlights-new-preclinical-data-identifying-role-of-tusc2-the-6752835)
- 2026-09-08 12:00 UTC [Conference Announcement] [Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference](https://www.quantisnow.com/insight/genprex-to-present-at-the-hc-wainwright-28th-annual-global-6707575)
- 2026-08-18 11:01 UTC [SEC Form 8-K] [Genprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/genprex-inc-filed-sec-form-8-k-other-events-financial-statements-6685826)
- 2026-08-18 11:00 UTC [Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy](https://www.quantisnow.com/insight/genprex-selects-leading-clinical-and-commercial-contract-development-and-manufacturing-6685819)
- 2026-08-14 13:27 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Genprex Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-genprex-inc-6682156)
- 2026-08-05 20:31 UTC [SEC Form 8-K] [Genprex Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits](https://www.quantisnow.com/insight/genprex-inc-filed-sec-form-8-k-notice-of-delisting-or-6665852)
- 2026-08-03 11:02 UTC [SEC Form 8-K] [Genprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/genprex-inc-filed-sec-form-8-k-other-events-financial-statements-6658642)
- 2026-08-03 11:00 UTC [Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies](https://www.quantisnow.com/insight/genprex-announces-collaboration-with-roche-diagnostics-for-biomarker-assay-validation-6658627)
- 2026-07-30 20:31 UTC [SEC Form 8-K] [Genprex Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/genprex-inc-filed-sec-form-8-k-notice-of-delisting-or-6656423)
- 2026-07-14 13:23 UTC [SEC Form 8-K] [Genprex Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/genprex-inc-filed-sec-form-8-k-material-modification-to-rights-6636363)
- 2026-06-26 20:46 UTC [SEC Form S-8] [SEC Form S-8 filed by Genprex Inc.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-genprex-inc-6617634)
- 2026-06-22 13:02 UTC [SEC Form 8-K] [Genprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/genprex-inc-filed-sec-form-8-k-other-events-financial-statements-6610269)
- 2026-06-22 13:00 UTC [Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer](https://www.quantisnow.com/insight/genprex-receives-a-notice-of-allowance-from-the-canadian-intellectual-6610251)
- 2026-06-18 20:01 UTC [SEC Form 8-K] [Genprex Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/genprex-inc-filed-sec-form-8-k-leadership-update-submission-of-6608446)
- 2026-06-17 13:00 UTC [Genprex to Participate at BIO International Convention 2026](https://www.quantisnow.com/insight/genprex-to-participate-at-bio-international-convention-2026-6606099)
- 2026-06-12 21:05 UTC [SEC Form 8-K] [Genprex Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/genprex-inc-filed-sec-form-8-k-notice-of-delisting-or-6601047)
- 2026-06-05 21:01 UTC [SEC Form S-3] [SEC Form S-3 filed by Genprex Inc.](https://www.quantisnow.com/insight/sec-form-s-3-filed-by-genprex-inc-6591833)
- 2026-05-26 12:03 UTC [SEC Form 8-K] [Genprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/genprex-inc-filed-sec-form-8-k-other-events-financial-statements-6571372)
- 2026-05-26 12:00 UTC [Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting](https://www.quantisnow.com/insight/positive-clinical-data-on-biomarkers-in-patients-receiving-reqorsa-gene-6571339)
- 2026-05-14 12:05 UTC [SEC Form 8-K] [Genprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/genprex-inc-filed-sec-form-8-k-other-events-financial-statements-6552571)
- 2026-05-14 12:00 UTC [Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting](https://www.quantisnow.com/insight/genprex-collaborators-present-positive-preclinical-data-on-diabetes-gene-therapy-6552515)
- 2026-05-13 20:35 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Genprex Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-genprex-inc-6551350)
- 2026-04-30 12:00 UTC [SEC Form 8-K] [Genprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/genprex-inc-filed-sec-form-8-k-other-events-financial-statements-6523038)
- 2026-04-30 12:00 UTC [Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer](https://www.quantisnow.com/insight/genprex-receives-patent-grant-from-the-israel-patent-office-for-6522987)
- 2026-04-29 20:47 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Genprex Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-genprex-inc-6521804)
- 2026-04-28 11:07 UTC [SEC Form 8-K] [Genprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/genprex-inc-filed-sec-form-8-k-other-events-financial-statements-6517560)
- 2026-04-28 11:00 UTC [Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting](https://www.quantisnow.com/insight/genprex-collaborators-to-present-positive-preclinical-data-on-diabetes-gene-6517504)
- 2026-04-22 11:00 UTC [Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting](https://www.quantisnow.com/insight/positive-clinical-data-on-biomarkers-in-patients-receiving-reqorsa-gene-6509354)
- 2026-04-21 11:02 UTC [SEC Form 8-K] [Genprex Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/genprex-inc-filed-sec-form-8-k-regulation-fd-disclosure-other-6507543)
- 2026-04-21 11:00 UTC [Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy](https://www.quantisnow.com/insight/genprex-signs-sponsored-research-agreement-to-study-biomarkers-that-may-6507536)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/GNPX
- Earnings history: https://www.quantisnow.com/earnings/GNPX
- Dividend history: https://www.quantisnow.com/dividends/GNPX
- Insider transactions: https://www.quantisnow.com/insiders/GNPX
- Options chain: https://www.quantisnow.com/options/GNPX
- SEC 8-K filings only: https://www.quantisnow.com/company/GNPX/8-k
- RSS and alerts for GNPX: https://www.quantisnow.com/docs/rss-feeds.md
